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quantitative measures of liver function remained good.
These data are consistent with our own study compar-
ing DSRS and sclerotherapy which measured quan-
titative liver function. We showed that patients
successfully managed with sclerotherapy, who had no
major rebleeding, showed a significant improvement in
galactose elimination capacity over the first year 1.
Lesson: the data in this study show that neither of the
randomized therapies significantly accelerate liver fail-
ure compared to each other.
What of the high mortality and failure to achieve
surgical rescue of patients who failed sclerotherapy in
this study? This factor is the major difference between
this study and our previously published study. In the
Emory study only one patient randomized to scler-
otherapy died as a direct result of rebleeding, and 12
were successfully salvaged by surgical management. In
contrast, in the present study 8 patients died as a direct
result of rebleeding in the sclerotherapy group and
only 5 patients had surgical rescue. The authors cor-
rectly point out that access was a major problem for
their sclerotherapy patients who rebleed, and this high-
lights one of the shortcomings of sclerotherapy. What
are the lessons? In patients in whom sclerotherapy is
selected as primary management, a strategy should be
in place from the outset to treat rebleeding or consider
surgical treatment for persistent high risk varices.
Finally, it must be remembered that sclerotherapy
and surgical shunt are not the only treatments for
variceal bleeding. Liver transplant has dramatically
altered the management of patients with end-stage
liver disease. But, it is end-stage liver disease and not
variceal bleeding per se which is the indication for
transplant. However, in any patient who bleeds from
varices, full evaluation at the time of the initial bleed is
a critical step to help answer the question: is this
patient now, or will they in the future be a candidate for
liver transplant? The answer to that question will
influence treatment choice.We have recently published
an approach to the evaluation of such patients’. In
addition, the radiologists are back in the fray 5. Trans-
jugular intrahepatic portal system shunts (TIPS) can
provide portal decompression, but lack ofrandomized
trials and good objective data leave the role ofTIPS to
be defined.
In summary, the four prospective randomized trials
which have compared DSRS to sclerotherapy all show
better control of bleeding with decompressive shunt6.
Neither therapy appears to significantly accelerate
liver failure. Survival differs in these studies, and the
difference depends entirely on how patients who fail
sclerotherapy are managed. The important factors in
this are the type of patient, their access to care, and the
type of care available to the patient. To the physician
making management decisions, forward planning with
these factors in mind is the key.
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ENUCLEATION FOR GIANT LIVER
HAEMANGIOMA
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Cavernous hemangiomas are the most common benign tumors of the liver. Giant
cavernous hernangiomas, defined as those larger than 4crn in diameter, can reach
enormous proportions. Newer imaging rnodalities, although often demonstrating charac-
teristic features that strongly suggest the diagnosis, should not be augmented by biopsy
because of the risk of hemorrhage. Elective surgical resection may be indicated for
symptomatic giant lesions and for those with an atypical appearance where the diagnosis
is in doubt. Between October 1986 and May 1991, we treated 10 patients with giant
hernangiomas by enucleation or enucleation plus resection. Median operative blood loss
was 800 rnL (range 200 to 3000 mL). One patient required reoperation for control of
postoperative hemorrhage. Detailed pathologic examination has demonstrated an inter-
face between hemangiomas and the normal liver tissue that allows enucleation. Enuclea-
tion is an underused procedure that if carefully performed allows resection of giant
hernangiomas with a reduced blood loss and the preservation of virtually all normal
hepatic parenchyma.
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PAPER DISCUSSION
Hemangiomas are the most common benign non-
cystic tumors ofthe liver. Although common, they/area
symp-tomatic in most patients. Only patients with
symptomatic giant hemangiomas (> 4 cm) usually
require resection. Baer et al., have recently addressed
the technical management of such patients and have
clearly described enucleation as an alternative tech-
nique for successful management. Broader application
of this technical approach should be considered in the
surgical management of patients with symptomatic
hepatic hemangiomas.
Baer et al., employed enucleation in 10 patients with
symptomatic giant cavernous hemangiomas. Pre-
operative imaging included computed tomography
and selective hepatic angiography. Hemangiomas
ranged from 7 to 25 cm in greatest diameter. All but
two of the hemangiomas involved the central li;eer
segments IV and V and all of the hemangiomas
involved two or more liver segments. Their technique
consisted of liver mobilization, extrahepatic ligation of
the arterial supply to the hemangioma, and blunt
dissection of the hemangioma from the normal paren-
chyma with suture ligation ofthe involved intrahepatic
vessels and bile ducts. Intermittent inflow vascular
occlusion was used during parenchymal dissection.
Median blood loss was 800mL (range 200 to 3000 mL).
There were no deaths and only one major complication
which consisted hemorrhage requiring reoperation for
control. Postoperative follow-up after dismissal was
not detailed.
The clinical report by Baer et al., dispels the myth
propagated by some surgeons that safe resection of
giant hemangiomas requires complete resection with
a margin of normal liver parenchyma. Fear of uncon-
trollable hemorrhage along the interface between the
hemangioma and adjacent normal parenchyma and
the concern that microscopic residual hemangioma
would ’recur’ or grow and cause recurrent symptoms
have been used as the rationale by proponents of
resection. Although Baer et al., provide no data to
refute the latter premise (nor was it their intention to do
so), they have provided descriptive data supporting the
efficacy of enucleation. They have shown pathologi-
cally that a pseudocapsule exists adjacent to the hem-
angioma and that it is useful clinically as a plane for
excision. Although enucleation has been used selective-
ly by others, Baer et al., have shown that this technique
can be used for giant hemangiomas regardless of in-
trahepatic location. Their technique permits preserva-
tion of all normal parenchyma. It obviates transection
of adjacent parenchyma which may harbor unrecog-
nized ducts and vessels displaced by the hemangioma
which, if injured, can cause significant postoperative
complications. Quite simply, the described technique
permits the surgeon to safely focus on excision of the
tumor with optimal preservation of adjacent liver.
Should enucleation be the technique of choice for
excision of symptomatic hepatic hemangiomas? May-
be, but several factors need further analysis before
general acce-ptance into clinical practice. Obviously
hemorrhage is the major life threatening risk during
resection ofhepatic hemangiomas and Baer et al., have
utilized hepatic artery ligation and intermittent inflow
vascular occlusion to reduce this risk. Whether either
of these adjuncts to enucleation are essential remains
unproven. Importantly 50% of the patients in whomHPB INTERNATIONAL 69
enucleation was employed had an operative blood loss
exceeding 1400mL. Depending upon intraoperative
hemodynamics, blood products were pro-bably trans-
fused in some patients. Albeit infrequent, transfusion
related risks can be life threatening. Ideally a surgical
technique for benign disease should eliminate any
transfusion risk when employed. Did the adjuncts used
herein .reduce blood loss? Unfortunately the data pres-
ented by Baer et al., leaves this question unanswered
because there are no data for comparison. Is the ration-
ale for arterial ligation sound? Substantiation that
preoperative angiography identified the exact arterial
supply to the hemangioma would support their con-
tention that extrahepatic ligation of the major hepatic
arterial branch to the hemangioma is advantageous.
However, that data was not presented. Moreover the
concept is suspect because the classic arterial supply to
hepatic hemangiomas is through multiple small pe-
ripheral arteries rather than a single dominant branch
arising extrahepatically from a main lobar hepatic
artery. If heman-giomas are enucleated, the arterial
supply will be ligated immediately adjacent to the
hemangioma anyway. Whether extrahepatic ligation
confers any additional benefit is unknown. Finally
Baer et al., favor intermittent vascular inflow occlusion
to the liver during enucleation. Unless the time for
enucleation of the hemangioma from the parenchyma
routinely exceeded 45-60 minutes, continuous rather
than intermittent occlusion would likely be more effec-
tive in reducing blood loss because intermittent perfu-
sion of the interface would be avoided.
Although the exact technique for resection of hema-
ngiomas may not need to be so elaborate, the concept
ofbroader application oflocal resection or enucleation
is laudable. Utilization ofthe plane ofcompressed liver
parenchyma adjacent to the hemangioma during con-
tinuous inflow vascular occlusion should allow enuc-
leation to be performed safely without sacrifice of
adjacent normal liver and without any permanent liver
ischemia. The technique of Baer et al., should be
heeded. Refinements will follow.
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ACUTE VARICEAL BLEEDING: SOMATOSTATIN
OR SCLEROTHERAPY?
ABSTRACT
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C.A., Gilmore, I., Morris, A. I., Ashby, D. and West, C. R. (1992) A prospective ran-
domised controlled trial comparing the efficacy of somatostatin with injection sclero-
therapy in the control of bleeding oesophageal varices. Journal of Hepatology 16,
128-137.
Since previous reports have suggested that somatostatin may be of value in the control of
acute variceal haemorrhage, we compared its efficacy with that of injection sclerotherapy
in a randomised controlled clinical trial. Eighty consecutive patients with endoscopically-
proven severe variceai bleeding were randomised to injection sclerotherapy (n--41) or
somatostatin (n-- 39) given as a continuous infusion of 250 pg/h for 5 days plus daily
bolus administration of 250 pg. The efficacy of injection sclerotherapy and somatostatin
infusion in controlling haemorrhage and preventing rebleeding (censored at 5days),
mortality (censored at 28 days) and complications was compared. The aetiology of the
portal hypertension and transfusion requirementswas similar between the two groups, but
there were more patients with severe liver disease (Child’s C) in the somatostatin group.